Serina Therapeutics Files 8-K
Ticker: SER · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, corporate-filing
TL;DR
Serina Therapeutics filed an 8-K on 10/6/25. Standard reporting.
AI Summary
Serina Therapeutics, Inc. filed an 8-K on October 6, 2025, reporting other events and financial statements. The company, formerly known as AgeX Therapeutics, Inc. until June 6, 2017, is incorporated in Delaware and headquartered in Huntsville, Alabama.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain any material adverse information.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- AgeX Therapeutics, Inc. (company) — Former name
- October 6, 2025 (date) — Date of Report
- Huntsville, Alabama (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" for Serina Therapeutics, Inc.
When was this Form 8-K filed?
This Form 8-K was filed on October 6, 2025.
What was Serina Therapeutics, Inc. formerly known as?
Serina Therapeutics, Inc. was formerly known as AgeX Therapeutics, Inc.
In which state is Serina Therapeutics, Inc. incorporated?
Serina Therapeutics, Inc. is incorporated in Delaware.
What is the address of Serina Therapeutics, Inc.'s principal executive offices?
The address of Serina Therapeutics, Inc.'s principal executive offices is 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-10-06 16:12:48
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate
- $5 million — nnounced that it has received the first $5 million of funding under the previously announc
Filing Documents
- ser-20251006.htm (8-K) — 23KB
- ex991_ser-5mfirsttranchexp.htm (EX-99.1) — 9KB
- 0001708599-25-000122.txt ( ) — 231KB
- ser-20251006.xsd (EX-101.SCH) — 2KB
- ser-20251006_lab.xml (EX-101.LAB) — 53KB
- ser-20251006_pre.xml (EX-101.PRE) — 31KB
- ser-20251006_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 6, 2025, Serina Therapeutics, Inc., a Delaware corporation (the "Company"), announced that it has received the first $5 million of funding under the previously announced unsecured convertible note (the "Convertible Note") dated September 9, 2025. Additional information regarding the Convertible Note is set forth in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on September 15, 2025.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated October 06 , 2025, issued by Serina Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: October 6, 2025 By: /s/ Steve Ledger Chief Executive Officer